10 Best Weight Loss Drug Stocks to Buy in 2026

7. Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Number of Hedge Fund Holders: 52

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best weight loss drugs on this list.

TheFly reported on June 8 that TEVA announced new clinical and real-world findings supporting the use of Austedo and Austedo XR in patients with tardive dyskinesia. Results from the IMPACT-TD study showed that patients with mild symptoms experienced improvements in involuntary movements and daily functioning after treatment. The company also reported updated data from the ongoing three-year RIM-TD study, where more than half of participants achieved a treatment response by week 15, while additional patients showed benefits with continued therapy beyond that period. The findings highlighted the potential value of long-term treatment and reinforced Teva’s efforts to improve disease management and outcomes for individuals living with tardive dyskinesia.

Second, it was announced on June 4 that Teva Pharmaceutical Industries Limited (NYSE:TEVA) expanded its footprint in international markets through the European rollout of AHZANTIVE, an aflibercept biosimilar. The launch began across several countries, including France, Germany, Spain, and the Netherlands, with additional market entries planned later in the year. The product broadens TEVA’s biosimilars portfolio and strengthens its position in ophthalmology. Approved for multiple retinal disorders, AHZANTIVE offers an additional treatment option for patients with vision-threatening conditions. The launch also reflects TEVA’s strategy of increasing access to biologic medicines through partnerships, commercial expansion, and a growing biosimilars business.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) is a global pharmaceutical company advancing its growth strategy through generic GLP-1 treatments. By launching generic versions of liraglutide-based weight-loss and diabetes drugs, Teva aims to improve affordability and access in the growing obesity treatment market.